UNICREDIT BANK/CALL/ELI LILLY & CO/1100/0.1/14.01.26 | Real-time BOERSE MUENCHEN 05:41:37 2024-07-16 am EDT | ||
| 10.92 EUR | 0.00% |
|
| Current month | +18.70% | ||
| 1 month | +31.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 10.92 | 0.00% |
| 24-07-15 | 10.92 | +4.80% |
| 24-07-12 | 10.42 | +5.15% |
| 24-07-11 | 9.91 | -2.27% |
| 24-07-10 | 10.14 | +8.92% |
Real-time BOERSE MUENCHEN
Last update July 16, 2024 at 05:41 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD2FCM |
| ISIN | DE000HD2FCM3 |
| Date issued | 2024-02-05 |
| Strike | 1,100 $ |
| Maturity | 2026-01-14 (548 Days) |
| Parity | 10 : 1 |
| Emission price | 3.38 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.92 € |
|---|---|
| Lowest since issue | 3.25 € |
| Spread | 1.96 € |
| Spread % | 16.47% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
950.5
USD
Average target price
893.1
USD
Spread / Average Target
-6.04%
- Stock Market
- Warrants
- Warrant
